Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

177.05 +5.32 (+3.10%)
Streaming Delayed Price Updated: 10:12 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
70 71 Next >
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
You should do your best to avoid making similar mistakes too. 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
The company is grappling with losing Humira's patent protection in 2023. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
24 Top Dividend Stocks to Buy and Hold in 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond. 
Via The Motley Fool
Big Players' Recent Trades in ABBV Options
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
Peering Into AbbVie's Recent Short Interest
Via Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
There's more than meets the eye with all three of these dividend stocks. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Market Whales and Their Recent Bets on ABBV Options
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
1 Concerning Trend for AbbVie Investors to Keep an Eye On
Is AbbVie a good stock for dividend investors to own? 
Via The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
3 Top Dividend Growth Stocks to Buy in 2024
Income investors should love these great stocks. 
Via The Motley Fool
The 3 Hottest Dividend Stocks to Watch in 2024
With 2023 in the books and the entirety of 2024 ahead of us, here are compelling dividend stocks to watch for astute investors. 
Via InvestorPlace
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with. 
Via The Motley Fool
Topics ETFs Retirement
Exposures Pension
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Getting going on investing is a terrific way to start 2024. 
Via The Motley Fool
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024
These companies pay attractive dividends that should continue rising. 
Via The Motley Fool
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Common Investing Mistake: Income Obsession (& More)
A common investing mistake is income obsession. Others are holding too many stocks and focusing on valuation to know if the price of a stock is right. Sounds familiar? Any of these mistakes hurts your... 
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Small Caps Are On A Tear Including Speculative Biotechs
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
The acquisition fills an immediate need with some extras to boot. 
Via The Motley Fool
29 Undervalued Dividend Aristocrats: December 2023
The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Better Growth Stock: AbbVie vs. Abbott Laboratories
Do Humira's declining sales give Abbott Laboratories the edge as the better growth stock? 
Via The Motley Fool
7 Blue-Chip Dividend Stocks to Buy Before Dec. 31
Always a strong investment, blue-chip dividend stocks continue to make sense as 2023 draws closer to an end and 2024 nears. 
Via InvestorPlace
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
70 71 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.